PortalPublikationenAmsacrine combined with etoposide and high-dose methylpredni...

Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.

Standard

Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children. / Horstmann, Martin; Hassenpflug, Wolf-Achim; Udo, Zur Stadt; Escherich, Gabriele; Janka-Schaub, Gritta; Kabisch, Hartmut.

in: HAEMATOLOGICA, Jahrgang 90, Nr. 12, 12, 2005, S. 1701-1703.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Horstmann, M, Hassenpflug, W-A, Udo, ZS, Escherich, G, Janka-Schaub, G & Kabisch, H 2005, 'Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.', HAEMATOLOGICA, Jg. 90, Nr. 12, 12, S. 1701-1703. <http://www.ncbi.nlm.nih.gov/pubmed/16330449?dopt=Citation>

APA

Horstmann, M., Hassenpflug, W-A., Udo, Z. S., Escherich, G., Janka-Schaub, G., & Kabisch, H. (2005). Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children. HAEMATOLOGICA, 90(12), 1701-1703. [12]. http://www.ncbi.nlm.nih.gov/pubmed/16330449?dopt=Citation

Vancouver

Horstmann M, Hassenpflug W-A, Udo ZS, Escherich G, Janka-Schaub G, Kabisch H. Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children. HAEMATOLOGICA. 2005;90(12):1701-1703. 12.

Bibtex

@article{73d317846fd34b09984fd7741e891bbd,
title = "Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.",
abstract = "In a retrospective analysis of 24 children with refractory or multiply relapsed acute lymphoblastic leukemia (ALL), a salvage regimen comprising amsacrine, etoposide, and high-dose methylprednisolone AEP achieved a significant treatment response in 11 of 19 evaluable patients (8 complete and 3 partial remissions). Five of 9 AEP-responsive patients who underwent subsequent stem cell transplantation are alive (median follow-up: 43 months; range 10 to 91). The load of minimal residual disease prior to transplantation appears to be predictive for outcome in this very poor-prognosis subgroup of ALL.",
author = "Martin Horstmann and Wolf-Achim Hassenpflug and Udo, {Zur Stadt} and Gabriele Escherich and Gritta Janka-Schaub and Hartmut Kabisch",
year = "2005",
language = "Deutsch",
volume = "90",
pages = "1701--1703",
journal = "HAEMATOLOGICA",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "12",

}

RIS

TY - JOUR

T1 - Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.

AU - Horstmann, Martin

AU - Hassenpflug, Wolf-Achim

AU - Udo, Zur Stadt

AU - Escherich, Gabriele

AU - Janka-Schaub, Gritta

AU - Kabisch, Hartmut

PY - 2005

Y1 - 2005

N2 - In a retrospective analysis of 24 children with refractory or multiply relapsed acute lymphoblastic leukemia (ALL), a salvage regimen comprising amsacrine, etoposide, and high-dose methylprednisolone AEP achieved a significant treatment response in 11 of 19 evaluable patients (8 complete and 3 partial remissions). Five of 9 AEP-responsive patients who underwent subsequent stem cell transplantation are alive (median follow-up: 43 months; range 10 to 91). The load of minimal residual disease prior to transplantation appears to be predictive for outcome in this very poor-prognosis subgroup of ALL.

AB - In a retrospective analysis of 24 children with refractory or multiply relapsed acute lymphoblastic leukemia (ALL), a salvage regimen comprising amsacrine, etoposide, and high-dose methylprednisolone AEP achieved a significant treatment response in 11 of 19 evaluable patients (8 complete and 3 partial remissions). Five of 9 AEP-responsive patients who underwent subsequent stem cell transplantation are alive (median follow-up: 43 months; range 10 to 91). The load of minimal residual disease prior to transplantation appears to be predictive for outcome in this very poor-prognosis subgroup of ALL.

M3 - SCORING: Zeitschriftenaufsatz

VL - 90

SP - 1701

EP - 1703

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

IS - 12

M1 - 12

ER -